Tutte le categorie
| Product Name | Descrizione | Action |
|---|---|---|
| Sacituzumab govitecan,Trodelvy,TROP-2,IMMU-132,Oncology ADC / Triple-negative breast cancer ADC / Urothelial cancer ADC,CAS no. 1491917-83-9 | Trade Name : Trodelvy Target : TROP-2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 1014(First three quarters) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Risankizumab ,Skyrizi ,Anticorpo bispecifico ,BI 655066 ,Inibitore dell'interleuchina / inibitore dell'IL-23 ,Biologico immunologico ,Anticorpo monoclonale ,N. CAS 1612838-76-2 | Trade Name : Skyrizi Target : Bispecific antibody Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 13000~15000(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch ... |
|
| Tezepelumab, Tesspire, TSLP, Anticorpo monoclonale, AMG 157, Biologico anti-TSLP, Biologico respiratorio / Astmologico, CAS n. 1572943-60-0 | Trade Name : Tezspire Target : TSLP Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 826(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Dupilumab,Dupixent,REGN668,inibitore dei recettori delle interleuchine,immunologico biologico,anticorpo monoclonale, CAS n.1190264-60-8 | Trade Name : Dupixent Target : N/A Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 1340(First three quarters) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Ialuronidasi, Enzima / Enzima ricombinante, Escipiente biologico / Componente della co-formulazione biologica, CAS n. 9001-54-1 | Trade Name : N/A Target : N/A Molecular Type : Enzymes Sales in 2025 (Millions of USD) : 1300~1375(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Etanercept, Enbrel, Erelzi, Eticovo, Biologico anti- TNF / inibitore del TNF, Fusion Protein, CAS n. 185243-69-0 | Trade Name : Enbrel Target : N/A Molecular Type : Fusion Protein Sales in 2025 (Millions of USD) : 2300~2500(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Pertuzumab | Trade Name : Perjeta Target : N/A Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 2800(First three quartersestimate ) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch ... |
|
| Tocilizumab | Trade Name : Actemra Target : N/A Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 1280(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
